There are currently four agents that target IL-23 in clinical use for psoriasis: ustekinumab(PASI 75: 64%, week 12), which blocks the common p40 subunit of IL-12 and IL-23, and guselkumab(PASI 90: 73%, week 16), risankizumab(PASI 90: 75%, week 16), and tildrakizumab(PASI 75: 64%, week 12), which target the p19 subunit of IL-23 [8]. This evidence concerns the gene IL37 and psoriasis.